Monoamine Oxidases as Potential Contributors to Oxidative Stress in Diabetes: Time for a Study in Patients Undergoing Heart Surgery

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Duicu, Oana M ^a   Lighezan, Rodica ^a   Sturza, Adrian ^a   Ceausu, Raluca A ^a   Borza, Claudia ^a   Vaduva, Adrian ^a   Noveanu, Lavinia ^a   Gaspar, Marian ^a   Ionac, Adina ^a   Feier, Horea ^a   Muntean, Danina M ^a   Mornos, Cristian ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); MONOAMINE OXIDASE INHIBITOR; REACTIVE OXYGEN METABOLITE;

CARDIOVASCULAR SYSTEM; DIABETES MELLITUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; HEART FAILURE; HEART SURGERY; HUMAN; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; RESPIRATORY CHAIN; REVIEW; DRUG EFFECTS; ENZYMOLOGY; HEART MITOCHONDRION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; THORAX SURGERY;

GYMNOMYZA;

DIABETES COMPLICATIONS; DIABETES MELLITUS; HEART FAILURE; HUMANS; MITOCHONDRIA, HEART; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; THORACIC SURGERY;

EID: 84935884727     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/515437     Document Type: Review

References (99)

1. A. S. Go, D. Mozaffarian, V. L. Roger et al., "Heart disease and stroke statistics-2014 update: a report from the American Heart Association," Circulation, vol. 129, no. 3, pp. e28-e292, 2014.
2. L. Guariguata, D. R. Whiting, and I. Hambleton, "Global estimates of diabetes prevalence for 2013 and projections for 2035," Diabetes Research and Clinical Practice, vol. 103, no. 2, pp. 137-149, 2014.
3. Authors/Task Force Members, L. Ryden, P. J. Grant et al., "ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the EuropeanAssociation for the Study of Diabetes (EASD)," EuropeanHeart Journal, vol. 34, no. 39, pp. 3035-3087, 2013.
4. I. Martin-Timon, C. Sevillano-Collantes, A. Segura-Galindo et al., "Type 2 diabetes and cardiovascular disease: have all risk factors the same strength?" World Journal of Diabetes, vol. 5, no. 4, pp. 444-470, 2014.
5. W. B. Kannel and D. L. McGee, "Diabetes and cardiovascular disease. The Framingham study," The Journal of the American Medical Association, vol. 241, no. 19, pp. 2035-2038, 1979.
6. S. Boudina and E. D. Abel, "Diabetic cardiomyopathy revisited," Circulation, vol. 115, no. 25, pp. 3213-3223, 2007.
7. D. B. Zorov, C. R. Filburn, L.-O. Klotz, J. L. Zweier, and S. J. Sollott, "Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes," The Journal of ExperimentalMedicine, vol. 192, no. 7, pp. 1001-1014, 2000.
8. D. B. Zorov, M. Juhaszova, and S. J. Sollott, "Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release," Physiological Reviews, vol. 94, no. 3, pp. 909-950, 2014.
9. A. Daiber, "Redox signaling (cross-talk) fromand to mitochondria involves mitochondrial pores and reactive oxygen species," Biochimica et Biophysica Acta: Bioenergetics, vol. 1797, no. 6-7, pp. 897-906, 2010.
10. S. Karbach, P. Wenzel, A. Waisman et al., "eNOS uncoupling in cardiovascular diseases-the role of oxidative stress and inflammation," Current Pharmaceutical Design, vol. 20, no. 22, pp. 3579-3594, 2014.
11. R. P. Brandes, N. Weissmann, and K. Schrder, "Redoxmediated signal transduction by cardiovascular Nox NADPH oxidases," Journal of Molecular and Cellular Cardiology, vol. 73, pp. 70-79, 2014.
12. A. Sturza, M. S. Leisegang, A. Babelova et al., "Monoamine oxidases are mediators of endothelial dysfunction in the mouse aorta," Hypertension, vol. 62, no. 1, pp. 140-146, 2013.
13. M. A. Ismahil, T. Hamid, S. S. Bansal, B. Patel, J. R. Kingery, and S. D. Prabhu, "Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure: critical importance of the cardiosplenic axis," Circulation research, vol. 114, no. 2, pp. 266-282, 2014.
14. N. Glezeva and J. A. Baugh, "Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target," Heart Failure Reviews, vol. 19, no. 5, pp. 681-694, 2014.
15. M. M. J. vanGreevenbroek, C. G. Schalkwijk, and C. D. A. Stehouwer, "Obesity-associated low-grade inflammation in type 2 diabetes mellitus: causes and consequences," Netherlands Journal of Medicine, vol. 71, no. 4, pp. 174-187, 2013.
16. K. Fujiu and R. Nagai, "Contributions of cardiomyocyte-cardiac fibroblast-immune cell interactions in heart failure development," Basic Research in Cardiology, vol. 108, no. 4, article 357, 2013.
17. R. Zhou, A. S. Yazdi, P. Menu, and J. Tschopp, "A role for mitochondria in NLRP3 inflammasome activation," Nature, vol. 469, no. 7329, pp. 221-226, 2011.
18. S. Kroller-Schon, S. Steven, S. Kossmann et al., "Molecular mechanisms of the crosstalk between mitochondria and NADPH oxidase through reactive oxygen species-studies in white blood cells and in animal models," Antioxidants and Redox Signaling, vol. 20, no. 2, pp. 247-266, 2014.
19. Z. V. Varga, Z. Giricz, L. Liaudet, G. Hasko, P. Ferdinandy, and P. Pacher, "Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy," Biochimica et Biophysica Acta (BBA):Molecular Basis of Disease, 2014.
20. J. Fuentes-Antras, A. M. Ioan, J. Tunon, J. Egido, and O. Lorenzo, "Activation of toll-like receptors and inflammasome complexes in the diabetic cardiomyopathy-associated inflammation," International Journal of Endocrinology, vol. 2014, Article ID 847827, 10 pages, 2014.
21. M. G. Rosca, B. Tandler, and C. L. Hoppel, "Mitochondria in cardiac hypertrophy and heart failure," Journal ofMolecular and Cellular Cardiology, vol. 55, no. 1, pp. 31-41, 2013.
22. M. Osterholt, T. D. Nguyen, M. Schwarzer, and T. Doenst, "Alterations in mitochondrial function in cardiac hypertrophy and heart failure," Heart Failure Reviews, vol. 18, no. 5, pp. 645-656, 2013.
23. C. E. Murdoch, M. Zhang, A. C. Cave, and A. M. Shah, "NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure," Cardiovascular Research, vol. 71, no. 2, pp. 208-215, 2006.
24. Y. Octavia, H. P. Brunner-La Rocca, and A. L. Moens, "NADPH oxidase-dependent oxidative stress in the failing heart: from pathogenic roles to therapeutic approach," Free Radical Biology and Medicine, vol. 52, no. 2, pp. 291-297, 2012.
25. R. Ventura-Clapier, A. Garnier, V. Veksler, and F. Joubert, "Bioenergetics of the failing heart," Biochimica et Biophysica Acta-Molecular Cell Research, vol. 1813, no. 7, pp. 1360-1372, 2011.
26. M. Zhang, A. C. Brewer, K. Schrder et al., "NADPH oxidase mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis," Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 42, pp. 18121-18126, 2010.
27. J. Kuroda, T. Ago, S. Matsushima, P. Zhai, M. D. Schneider, and J. Sadoshima, "NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart," Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 35, pp. 15565-15570, 2010.
28. J. F. Turrens, "Mitochondrial formation of reactive oxygen species," The Journal of Physiology, vol. 552, part 2, pp. 335-344, 2003.
29. M. P. Murphy, "How mitochondria produce reactive oxygen species," Biochemical Journal, vol. 417, no. 1, pp. 1-13, 2009.
30. A. Nickel, M. Kohlhaas, and C. Maack, "Mitochondrial reactive oxygen species production and elimination," Journal ofMolecular and Cellular Cardiology, vol. 73, pp. 26-33, 2014.
31. N. Kaludercic, J. Mialet-Perez, N. Paolocci, A. Parini, and F. Di Lisa, "Monoamine oxidases as sources of oxidants in the heart," Journal ofMolecular and Cellular Cardiology, vol. 73, pp. 34-42, 2014.
32. E. Schulz, P. Wenzel, T. Munzel, and A. Daiber, "Mitochondrial redox signaling: interaction of mitochondrial reactive oxygen species with other sources of oxidative stress," Antioxidants and Redox Signaling, vol. 20, no. 2, pp. 308-324, 2014.
33. E. J. Lesnefsky, S. Moghaddas, B. Tandler, J. Kerner, and C. L. Hoppel, "Mitochondrial dysfunction in cardiac disease: ischemia-reperfusion, aging, and heart failure," Journal of Molecular and Cellular Cardiology, vol. 33, no. 6, pp. 1065-1089, 2001.
34. C. M. Sag, C. X. C. Santos, and A. M. Shah, "Redox regulation of cardiac hypertrophy," Journal of Molecular and Cellular Cardiology, vol. 73, pp. 103-111, 2014.
35. E. D. Abel and T. Doenst, "Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy," Cardiovascular Research, vol. 90, no. 2, pp. 234-242, 2011.
36. T. Liu and B. ORourke, "Regulation of mitochondrial Ca2+ and its effects on energetics and redox balance in normal and failing heart," Journal of Bioenergetics and Biomembranes, vol. 41, no. 2, pp. 127-132, 2009.
37. M. Luo and M. E. Anderson, "Mechanisms of altered Ca2+ handling in heart failure," Circulation Research, vol. 113, no. 6, pp. 690-708, 2013.
38. H. Tsutsui, S. Kinugawa, and S. Matsushima, "Oxidative stress and heart failure," American Journal of Physiology: Heart and Circulatory Physiology, vol. 301, no. 6, pp. H2181-H2190, 2011.
39. T. Doenst, T. D. Nguyen, and E. D. Abel, "Cardiacmetabolismin heart failure: implications beyond atp production," Circulation Research, vol. 113, no. 6, pp. 709-724, 2013.
40. A. N. Carley, H. Taegtmeyer, and E. D. Lewandowski, "Mechanisms linking energy substrate metabolism to the function of the heart," Circulation Research, vol. 114, no. 4, pp. 717-729, 2014.
41. H. Ardehali, H. N. Sabbah, M. A. Burke et al., "Targeting myocardial substrate metabolism in heart failure: potential for new therapies," European Journal of Heart Failure, vol. 14, no. 2, pp. 120-129, 2012.
42. S. Neubauer, "Thefailing heart-an engine out of fuel," The New England Journal ofMedicine, vol. 356, no. 11, pp. 1140-1151, 2007.
43. W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk, "Myocardial substrate metabolism in the normal and failing heart," Physiological Reviews, vol. 85, no. 3, pp. 1093-1129, 2005.
44. H. M. Viola and L. C. Hool, "Targeting calcium and the mitochondria in prevention of pathology in the heart," Current Drug Targets, vol. 12, no. 5, pp. 748-760, 2011.
45. A. Herrero and G. Barja, "Localization of the site of oxygen radical generation inside the complex I of heart and nonsynaptic brain mammalian mitochondria," Journal of Bioenergetics and Biomembranes, vol. 32, no. 6, pp. 609-615, 2000.
46. D. Han, E. Williams, and E. Cadenas, "Mitochondrial respiratory chain-dependent generation of superoxide anion and its release into the intermembrane space," Biochemical Journal, vol. 353, no. 2, pp. 411-416, 2001.
47. F. L. Muller, Y. Liu, and H. Van Remmen, "Complex III releases superoxide to both sides of the inner mitochondrialmembrane," Journal of Biological Chemistry, vol. 279, no. 47, pp. 49064-49073, 2004.
48. J. St-Pierre, J. A. Buckingham, S. J. Roebuck, and M. D. Brand, "Topology of superoxide production from different sites in the mitochondrial electron transport chain," The Journal of Biological Chemistry, vol. 277, no. 47, pp. 44784-44790, 2002.
49. Y.-R. Chen and J. L. Zweier, "Cardiacmitochondria and reactive oxygen species generation," Circulation Research, vol. 114, no. 3, pp. 524-537, 2014.
50. A. Y. Andreyev, Y. E. Kushnareva, and A. A. Starkov, "Mitochondrial metabolism of reactive oxygen species," Biochemistry, vol. 70, no. 2, pp. 200-214, 2005.
51. T. Ide, H. Tsutsui, S. Kinugawa et al., "Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium," Circulation Research, vol. 85, no. 4, pp. 357-363, 1999.
52. T. Ide, H. Tsutsui, S. Kinugawa et al., "Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium," Circulation Research, vol. 86, no. 2, pp. 152-157, 2000.
53. J. Marin-Garcia, M. J. Goldenthal, and G. W. Moe, "Abnormal cardiac and skeletal muscle mitochondrial function in pacinginduced cardiac failure," Cardiovascular Research, vol. 52, no. 1, pp. 103-110, 2001.
54. J. Marin-Garcia, M. J. Goldenthal, S. Damle, Y. Pi, and G. W. Moe, "Regional distribution of mitochondrial dysfunction and apoptotic remodeling in pacing-induced heart failure," Journal of Cardiac Failure, vol. 15, no. 8, pp. 700-708, 2009.
55. T. Doenst, G. Pytel, A. Schrepper et al., "Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload," Cardiovascular Research, vol. 86, no. 3, pp. 461-470, 2010.
56. M. Schwarzer, M. Osterholt, A. Lunkenbein et al., "Mitochondrial ROS production and respiratory complex activity in rats with pressure overload-induced heart failure," The Journal of Physiology, vol. 592, pp. 3767-3782, 2014.
57. E. R. Griffiths, I. Friehs, E. Scherr, D. Poutias, F. X. McGowan, and P. J. del Nido, "Electron transport chain dysfunction in neonatal pressure-overload hypertrophy precedes cardiomyocyte apoptosis independent of oxidative stress," Journal ofThoracic and Cardiovascular Surgery, vol. 139, no. 6, pp. 1609-1617, 2010.
58. G. C. Sparagna, A. J. Chicco, R. C. Murphy et al., "Lossof cardiac tetralinoleoyl cardiolipin in human and experimental heart failure," Journal of Lipid Research, vol. 48, no. 7, pp. 1559-1570, 2007.
59. T. Ide, H. Tsutsui, S. Hayashidani et al., "Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction," Circulation Research, vol. 88, no. 5, pp. 529-535, 2001.
60. M. G. Rosca, E. J. Vazquez, J. Kerner et al., "Cardiac mitochondria in heart failure: decrease in respirasomes and oxidative phosphorylation," Cardiovascular Research, vol. 80, no. 1, pp. 30-39, 2008.
61. M. G. Rosca and C. L. Hoppel, "New aspects of impaired mitochondrial function in heart failure," Journal of Bioenergetics and Biomembranes, vol. 41, no. 2, pp. 107-112, 2009.
62. V. G. Sharov, A. V. Todor, N. Silverman, S. Goldstein, and H. N. Sabbah, "Abnormal mitochondrial respiration in failed human myocardium," Journal ofMolecular and Cellular Cardiology, vol. 32, no. 12, pp. 2361-2367, 2000.
63. H. Lemieux, S. Semsroth, H. Antretter, D. Hofer, and E. Gnaiger, "Mitochondrial respiratory control and early defects of oxidative phosphorylation in the failing human heart," International Journal of Biochemistry and Cell Biology, vol. 43, no. 12, pp. 1729-1738, 2011.
64. R. J. Scheubel, M. Tostlebe, A. Simm et al., "Dysfunction of mitochondrial respiratory chain complex I in human failing myocardiumis not due to disturbedmitochondrial gene expression," Journal of theAmerican College of Cardiology, vol. 40, no. 12, pp. 2174-2181, 2002.
65. M. Bayeva, M. Gheorghiade, and H. Ardehali, "Mitochondria as a therapeutic target in heart failure," Journal of the American College of Cardiology, vol. 61, no. 6, pp. 599-610, 2013.
66. N. Stride, S. Larsen, M. Hey-Mogensen et al., "Decreased mitochondrial oxidative phosphorylation capacity in the human heart with left ventricular systolic dysfunction," European Journal of Heart Failure, vol. 15, no. 2, pp. 150-157, 2013.
67. O. Duicu, C. Jusca, L. Falnita et al., "Substrate-specific impairment ofmitochondrial respiration in permeabilized fibers from patients with coronary heart disease versus valvular disease," Molecular and Cellular Biochemistry, vol. 379, no. 1-2, pp. 229-234, 2013.
68. A. M. Cordero-Reyes, A. A. Gupte, K. A. Youker et al., "Freshly isolated mitochondria from failing human hearts exhibit preserved respiratory function," Journal of Molecular and Cellular Cardiology, vol. 68, pp. 98-105, 2014.
69. S. Boudina and E. D. Abel, "Diabetic cardiomyopathy, causes and effects," Reviews in Endocrine and MetabolicDisorders, vol. 11, no. 1, pp. 31-39, 2010.
70. R. Harmancey and H. Taegtmeyer, "Thecomplexities of diabetic cardiomyopathy: lessons from patients and animal models," Current Diabetes Reports, vol. 8, no. 3, pp. 243-248, 2008.
71. H. Bugger and E. D. Abel, "Mitochondria in the diabetic heart," Cardiovascular Research, vol. 88, no. 2, pp. 229-240, 2010.
72. R. Blake and I. A. Trounce, "Mitochondrial dysfunction and complications associated with diabetes," Biochimica et Biophysica Acta, vol. 1840, no. 4, pp. 1404-1412, 2014.
73. S. D. Martin and S. L. McGee, "The role of mitochondria in the aetiology of insulin resistance and type 2 diabetes," Biochimica et Biophysica Acta, vol. 1840, no. 4, pp. 1303-1312, 2014.
74. O. Lorenzo, E. Ramirez, B. Picatoste, J. Egido, and J. Tunon, "Alteration of energy substrates and ROS production in diabetic cardiomyopathy," Mediators of Inflammation, vol. 2013, Article ID461967, 11 pages, 2013.
75. C. E. Flarsheim, I. L. Grupp, and M. A. Matlib, "Mitochondrial dysfunction accompanies diastolic dysfunction in diabetic rat heart,"The American Journal of Physiology-Heart and Circulatory Physiology, vol. 271, no. 1, pp. H192-H202, 1996.
76. O. M. Lashin, P. A. Szweda, L. I. Szweda, and A. M. P. Romani, "Decreased complex II respiration and HNE-modified SDH subunit in diabetic heart," Free Radical Biology and Medicine, vol. 40, no. 5, pp. 886-896, 2006.
77. H. Bugger and E. D. Abel, "Rodentmodels of diabetic cardiomyopathy," Disease Models and Mechanisms, vol. 2, no. 9-10, pp. 454-466, 2009.
78. G. N. Pierce and N. S. Dhalla, "Heart mitochondrial function in chronic experimental diabetes in rats," Canadian Journal of Cardiology, vol. 1, no. 1, pp. 48-54, 1985.
79. Y. Tanaka, N. Konno, and K. J. Kako, "Mitochondrial dysfunction observed in situ in cardiomyocytes of rats in experimental diabetes," Cardiovascular Research, vol. 26, no. 4, pp. 409-414, 1992.
80. T. H. Kuo, K. H. Moore, F. Giacomelli, and J. Wiener, "Defective oxidative metabolism of heart mitochondria from genetially diabetic mice," Diabetes, vol. 32, no. 9, pp. 781-787, 1983.
81. S. Boudina, S. Sena, B. T. ONeill, P. Tathireddy, M. E. Young, and E. D. Abel, "Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity," Circulation, vol. 112, no. 17, pp. 2686-2695, 2005.
82. S. Boudina and E. D. Abel, "Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes," Physiology, vol. 21, no. 4, pp. 250-258, 2006.
83. E. R. Dabkowski, C. L. Williamson, V. C. Bukowski et al., "Diabetic cardiomyopathy-associated dysfunction in spatially distinct mitochondrial subpopulations," The American Journal of Physiology-Heart and Circulatory Physiology, vol. 296, no. 2, pp. H359-H369, 2009.
84. E. J. Anderson, A. P. Kypson, E. Rodriguez, C. A. Anderson, E. J. Lehr, and P. D. Neufer, "Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart," Journal of the American College of Cardiology, vol. 54, no. 20, pp. 1891-1898, 2009.
85. E. J. Anderson, E. Rodriguez, C. A. Anderson, K. Thayne, W. R. Chitwood, and A. P. Kypson, "Increased propensity for cell death in diabetic human heart is mediated by mitochondrialdependent pathways," American Journal of Physiology: Heart and Circulatory Physiology, vol. 300, no. 1, pp. H118-H124, 2011.
86. T. L. Croston, D. Thapa, A. A. Holden et al., "Functional deficiencies of subsarcolemmal mitochondria in the type 2 diabetic human heart," American Journal of Physiology. Heart and Circulatory Physiology, vol. 307, no. 1, pp. H54-H65, 2014.
87. D. Montaigne, X. Marechal, A. Coisne et al., "Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients," Circulation, 2014.
88. M. P. Stern, "Diabetes and cardiovascular disease: the "common soil" hypothesis," Diabetes, vol. 44, no. 4, pp. 369-374, 1995.
89. M. B. H. Youdim and J. P. M. Finberg, "New directions in monoamine oxidase A and B: selective inhibitors and substrates," Biochemical Pharmacology, vol. 41, no. 2, pp. 155-162, 1991.
90. M. Bortolato, K. Chen, and J. C. Shih, "Monoamine oxidase inactivation: from pathophysiology to therapeutics," Advanced Drug Delivery Reviews, vol. 60, no. 13-14, pp. 1527-1533, 2008.
91. P. Bianchi, O. Kunduzova, E. Masini et al., "Oxidative stress by monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis by serotonin and postischemic myocardial injury," Circulation, vol. 112, no. 21, pp. 3297-3305, 2005.
92. N. Kaludercic, E. Takimoto, T. Nagayama et al., "Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload," Circulation Research, vol. 106, no. 1, pp. 193-202, 2010.
93. N. Kaludercic, A. Carpi, T. Nagayama et al., "Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts," Antioxidants and Redox Signaling, vol. 20, no. 2, pp. 267-280, 2014.
94. M. E. Manni, M. Zazzeri, C. Musilli, E. Bigagli, M. Lodovici, and L. Raimondi, "Exposure of cardiomyocytes to angiotensin II induces over-activation ofmonoamine oxidase type A: implications in heart failure," European Journal of Pharmacology, vol. 718, no. 1-3, pp. 271-276, 2013.
95. O. Duicu, A. Sturza, L. Noveanu et al., "Mitochondria and endothelial dysfunction: a glimpse of monoamine oxidases," Experimental and Clinical Cardiology, supplement A, pp. 52A-56A, 2013.
96. A. Sturza, O. Duicu, and L. Noveanu, "Monoamine oxidase inhibition corrects endothelial dysfunction in experimental diabetes," Cardiovascular Research, vol. 2014, no. 103, p. P172, 2014.
97. E. J. Anderson, J. T. Efird, S. W. Davies et al., "Monoamine oxidase is a major determinant of redox balance in human atrial myocardium and is associated with postoperative atrial fibrillation," Journal of the American Heart Association, vol. 3, no. 1, Article ID e000713, 2014.
98. E. Braunwald, "Shattuck lecture cardiovascular medicine at the turn of themillennium: triumphs, concerns, and opportunities," The New England Journal of Medicine, vol. 337, no. 19, pp. 1360-1369, 1997.
99. R. P. Juni, H. J. Duckers, P. M. Vanhoutte, R. Virmani, and A. L. Moens, "Oxidative stress and pathological changes after coronary artery interventions," Journal of the American College of Cardiology, vol. 61, no. 14, pp. 1471-1481, 2013.